SamerKhaledMD

Oncology • Orlando, FL

Hematologic Oncology

Associate Professor

Join to view full profile

Dr. Khaled is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Khaled's full profile

Already have an account?

Office
1400 S Orange Ave
Orlando, FL 32806
Phone+1 321-843-2810

Fax+1 321-843-6330

Education & Training

Brooklyn Hospital CenterFellowship, Hematology and Medical Oncology, 2006 - 2009
Brooklyn Hospital CenterResidency, Internal Medicine, 2002 - 2006
Cairo University School of MedicineClass of 1998

Certifications & Licensure

CA State Medical License 2009 - 2025
FL State Medical License 2005 - 2025
NY State Medical License 2008 - 2016
American Board of Internal Medicine Hematology

Clinical Trials

Multi-center Study of Myeloablative Allo Stem Cell Transplant for Non-remission AML Using CloBu4 Regimen Start of enrollment: 2011 Nov 01
Completed
Phase 2
Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia, Acute Leukemia in Remission, or Chronic Myelomonocytic Leukemia Start of enrollment: 2014 Feb 10
Active, not recruiting
Phase 2
Safety and Efficacy Study of Pracinostat With Azacitadine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) Start of enrollment: 2013 Dec 24
Completed
Phase 2
Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA Start of enrollment: 2013 Dec 01
Completed
Phase 2
Cellular Immunotherapy in Treating Patients With High-Risk Acute Lymphoblastic Leukemia Start of enrollment: 2014 Oct 16
Active, not recruiting
Phase 1
Study Evaluating the Efficacy and Safety of JCAR015 in Adult B-cell Acute Lymphoblastic Leukemia (B-ALL) Start of enrollment: 2015 Aug 21
Terminated
Phase 2
Join now to see all

Publications & Presentations

PubMed

Correction: TET2 deficiency promotes MDS-associated leukemogenesis.
Feiteng Huang, Jie Sun, Wei Chen, Lei Zhang, Xin He
Blood Cancer Journal. 2023-11-28
Identifying signs and symptoms of AL amyloidosis in electronic health records using natural language processing, diagnosis codes, and manually abstracted registry data.
Eli Silvert, Laura Hester, Eshwan Ramudu, Colin Pawlowski, Britte Kranenburg
American Journal of Hematology. 2023-09-01
Donor-derived CD19-targeted chimeric antigen receptor T cells in adult transplant recipients with relapsed/refractory acute lymphoblastic leukemia.
Ibrahim Aldoss, Samer K Khaled, Yan Wang, Xiuli Wang, Joycelynne Palmer
Blood Cancer Journal. 2023-07-12

Abstracts/Posters

Effect of Co-Mutations and FLT3-ITD Variant Allele Frequency (VAF) on Response to Quizartinib or Salvage Chemotherapy (SC) in Relapsed/Refractory (R/R) Acute Myeloid L...
Samer K. Khaled, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Clinical and Immunologic Activity of Ipilimumab Following Decitabine Priming in Post-Allogeneic Transplant and Transplant-Na¥ve Patients with Relapsed or Refractory My...
Samer K. Khaled, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Characterization of Response and Transfusion Independence in Patients with FLT3-Internal Tandem Duplication (FLT3-ITD)_Mutated Relapsed/Refractory Acute Myeloid Leukem...
Samer K. Khaled, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Quality-Adjusted Time without Symptoms or Toxicity (Q-TWiST) Analysis of Quizartinib Vs Salvage Chemotherapy in Patients with Relapsed/Refractory (R/R) FLT3-ITD Acute ...
Samer K. Khaled, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Phase II Study of Oral Rigosertib Combined with Azacitidine (AZA) As First Line Therapy in Patients (Pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS)
Samer K. Khaled, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Pooled Safety Analysis of Quizartinib Monotherapy in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)Clinically Relevant Abstract
Samer K. Khaled, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Join now to see all

Lectures

Phase 2 Expansion Study of Oral Rigosertib Combined with Azacitidine (AZA) in Patients (Pts) with Higher-Risk (HR) Myelodysplastic Syndromes (MDS): Efficacy and Safety...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Clinical Outcomes of MDS Patients Who Were Allogeneic Hematopoietic Stem Cell Transplant Candidates but Did Not Proceed with Transplantation
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
MIPSS70+ V2.0 and Revised Cytogenetics Changes Predict Outcomes of Allogeneic Transplantation with Fludarabine and Melphalan Conditioning in Patients with Myelofibrosis
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

Omeros Corporation Reports Fourth Quarter and Year-End 2020 Financial ResultsMarch 1st, 2021
City of Hope Clinical and Laboratory Investigators Present New Research at the 60December 4th, 2018
City of Hope Doctors Present New Research on CAR T Cell Therapy, Bone Marrow Transplants and Other Treatments for Blood CancersNovember 19th, 2018
Join now to see all

SamerKhaledMD

Dr. Khaled is on Doximity

Education & Training

Certifications & Licensure

Clinical Trials

Publications & Presentations

Press Mentions

Viewing the full profile is available to verified healthcare professionals only.